PureTech Health (PureTech Health) 3-Year FCF Growth Rate : 4.50% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health 3-Year FCF Growth Rate?

PureTech Health's Free Cash Flow per Share for the six months ended in Dec. 2023 was $-0.15.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 4.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -10.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -29.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of PureTech Health was 4.50% per year. The lowest was -146.60% per year. And the median was -22.90% per year.

Competitive Comparison of PureTech Health's 3-Year FCF Growth Rate

For the Biotechnology subindustry, PureTech Health's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where PureTech Health's 3-Year FCF Growth Rate falls into.

PureTech Health 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

PureTech Health (OTCPK:PTCHF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

PureTech Health 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of PureTech Health's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health (PureTech Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (OTCPK:PTCHF) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

PRTC:USA PRTCl:UK PRTC:UK PRTCL:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.